Proteomics Profiling Identifies MCM4 as a Prognostic Biomarker for Postoperative Metastasis in Solid Pseudopapillary Neoplasms of the Pancreas | Synapse
March 3, 2026
Proteomics Profiling Identifies MCM4 as a Prognostic Biomarker for Postoperative Metastasis in Solid Pseudopapillary Neoplasms of the Pancreas
Key Points
MCM4 as a significant prognostic biomarker indicates relationship with postoperative metastasis.
The study shows a 75% accuracy in predicting metastasis associated with MCM4 levels.
Assessment using proteomics profiling enhances identification of critical biomarkers in pancreatic tumors.
Findings highlight MCM4's potential role in guiding postoperative treatment strategies for neoplasms.